Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia that accounting for 60% to 80% of all cases (Better, et al., 2023). According to world health organization (WHO), more than 55 million people globally live with dementia, and this number is expected to rise to 78 million by 2023 and 139 million by 2050 (WHO, 2021).
In the line with global epidemiology trend, the prevalence of AD is also rising at the regional level. In the United States, approximately 6.2 million individual aged 65 and older recently living with AD, and this figured is expected to reach 13.8 million by 2060 (Doher et al., 2023). Similarly, in Europe, the prevalence of AD is estimated at 5.05%, with a notably higher incidence in women (7.13%) as compared to men (3.31%) (Niu et al., 2017). Moreover, Asia alone has a higher prevalence of dementia patients than both America and Europe. A study conducted in tertiary care centers in Karachi showed that 63% of dementia patients had AD (Siddiqui et al., 2018).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
38
Experimental group will receive X boc kinect 360 bomb such as match makers, traffic control, mouse mayhem, strike a pose, pizza catch, flag frenzy, follow the arrow for 30 minutes for five days a week, for six weeks.
The intervention will run for 30 minutes (excluding rest period), five days a week, for six weeks (Deng, et al., 2025). The patients will take 1-2 minutes rest after 5 minutes of activity. Rest periods of 1-2 minutes after every 5 minutes of activity.
Ziauddin University
Karachi, Sindhi, Pakistan
Cognition
Cognitive function will be assessed through among mild to moderate AD patients where low values indicate decrease in cognitive ability.
Time frame: Baseline
Cognition
Cognitive function will be assessed through Mini- Cog among Mild to Moderate AD patients where low values indicate decrease cognitive function
Time frame: After 6 week of Intervention
Motor Function
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate poorer functional mobility
Time frame: Baseline
Motor Function
Motor function will be assessed using the Timed Up and Go (TUG) Test among patients with mild to moderate Alzheimer's disease (AD), where higher scores (longer completion times) indicate functional mobility
Time frame: After 6 week of intervention
Quality of Life (QOL)
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
Time frame: Baseline
Quality Of Life (QOL)
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease (QOL-AD) scale among patients with mild to moderate Alzheimer's disease. Lower scores indicate poorer quality of life, whereas higher scores indicate better perceived quality of life.
Time frame: After 6 weeks of Intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.